Mylan Inc (MYL) News 48.83 $MYL
Supreme Court Ignores Teva Pharmaceuticals Ltd's Pleas for Help
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 1:30PM CDT
Teva Pharmaceuticals is feverishly working to deflect revenue risk tied to the impending patent expiration for its highly popular multiple sclerosis drug Copaxone. The company's attempts to block potential generic biosimilars from coming to market...
Mylan (MYL) Approaches New Upside Target of $50.18
Comtex SmarTrend(R) - Fri Mar 28, 9:08AM CDT
Shares of Mylan (NASDAQ:MYL) opened today above their pivot of $48.55 and have already reached the first level of resistance at $49.38. Analysts will be watching for a cross of the next upside pivot targets of $50.18 and $51.81.
Is Teva Pharmaceutical Industries Ltd Turning a Corner?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Mar 27, 5:30PM CDT
Once a darling of the health care space (and a frequent member of "buy and hold forever" lists), Teva Pharmaceuticals spent about three and a half years in the market's doghouse. Investors bailed out due to worries about competition in the...
Morning Movers in Biotech: Clovis Oncology, Inc., Exact Sciences Corporation, GlaxoSmithKline PLC, a
George Budwell, The Motley Fool - Motley Fool - Thu Mar 27, 8:00AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Mylan Wins Breach of Contract Case against GlaxoSmithKline
PR Newswire - Thu Mar 27, 6:00AM CDT
Mylan Inc. (Nasdaq: MYL) today announced that, after a trial in the United States District Court for the District of New Jersey, a jury returned a verdict in favor of Mylan in its breach of contract lawsuit against GlaxoSmithKline (GSK) relating to Paroxetine Hydrochloride Extended-release (ER) Tablets. The jury decided that GSK owes Mylan $106.7 million in damages.
First Week Of MYL May 17th Options Trading
at The Street - Wed Mar 26, 11:57AM CDT
Investors in Mylan Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MYL options chain for the new May 17th contracts and identified one put and...
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
SmarTrend Watching for Potential Rebound in Shares of Mylan After 4.16% Loss
Comtex SmarTrend(R) - Mon Mar 24, 4:06PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $49.26 to a high of $52.41. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $52.02 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
District Court Upholds Mylan's U.S. Patents on Perforomist® Inhalation Solution
PR Newswire - Mon Mar 24, 12:27PM CDT
Mylan Inc. (Nasdaq: MYL) today announced the United States District Court for the Northern District of West Virginia issued a decision upholding the validity of all patents asserted by Mylan, protecting Perforomist® (formoterol fumarate) Inhalation Solution. Mylan previously sued Teva alleging that Teva's Abbreviated New Drug Application (ANDA) for this product infringed four Mylan patents covering Perforomist. After a full trial, the Court entered a judgment finding infringement of the patents-in-suit, rejecting Teva's defenses, and enjoining Teva from making, using, offering to sell, selling or importing the inhalation product described in Teva's ANDA. The Court's decision also prevents Teva's ANDA, which has yet to receive a tentative approval from the U.S. Food and Drug Administration (FDA), from receiving final approval prior to expiration of U.S. Patent Nos. 6,667,344; 6,814,953; 7,348,362; and 7,462,645, which cover Perforomist through June 2021.
New Product Offerings, Development and Research Collaboration, Upcoming Investor Conference, and Board Election - Analyst Notes on CVS Caremark, Teva, Zoetis, McKesson, and Mylan
PR Newswire - Mon Mar 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding CVS Caremark Corporation (NYSE: CVS), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Zoetis, Inc. (NYSE: ZTS), McKesson Corporation (NYSE: MCK), and Mylan, Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
This Generic Drug Threat Won't Go Away
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sat Mar 22, 12:35PM CDT
Editor's Note: In the video, Michael Douglass refers to a quote from Mylan's president. The quote is actually from the president of Mylan's North American operations, Anthony Mauro. The Fool regrets the error. "The unintended consequences of...
Pharmaceutical Equities under Review -- Research on Zoetis, Mylan, AVANIR Pharma and Actavis
PR Newswire - Fri Mar 21, 10:11AM CDT
The trading session on Thursday, March 20, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ Composite closed at 4,319.29, up 0.27%. The S&P 500 finished the session 0.60% higher at 1,872.01. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Mylan Inc. (NASDAQ: MYL), AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR) and Actavis PLC (NYSE: ACT). Free technical research on ZTS, MYL, AVNR and ACT can be downloaded upon signing up at:
Mixed News for Pfizer: A Good Chance to Buy?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 19, 8:30AM CDT
Last week was unusually eventful for Pfizer . The company, along with partner Bristol-Myers Squibb won a supplementary approval for its Factor Xa inhibitor. Pfizer also released some better than expected data from a pneumonia vaccine study that...
After Yesterday's Rally of 1.69% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Mar 17, 4:05PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $52.86 to a high of $54.22. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $53.89 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Mylan Rises 1.69% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Mar 17, 4:04PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $52.86 to a high of $54.22. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $53.89 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
15.8% Return Seen to Date on SmarTrend Mylan Call (MYL)
Comtex SmarTrend(R) - Mon Mar 17, 11:17AM CDT
SmarTrend identified an Uptrend for Mylan (NASDAQ:MYL) on February 14th, 2014 at $46.13. In approximately 1 month, Mylan has returned 15.85% as of today's recent price of $53.44.
Mylan Earnings Hindsight: Down 6.5% in Last 18 Days (MYL)
Comtex SmarTrend(R) - Mon Mar 17, 6:58AM CDT
Two weeks ago on February 27th, 2014 Mylan (NASDAQ:MYL) reported earnings and analysts, on average, expected earnings of $0.75 on sales of $1.8 billion. The company actually reported EPS of $0.78 on sales of $1.8 billion, beating EPS estimates by $0.03 and beating revenue estimates by $3.1 million. Shares of Mylan have slipped from $56.27 to $52.63, representing a loss of 6.5%, since the company reported earnings 18 days ago.
4 Stocks Breaking Out on Big Volume
at The Street - Mon Mar 17, 6:57AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Supreme Court Ignores Teva Pharmaceuticals Ltd's Pleas for Help
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 1:30PM CDT
Teva Pharmaceuticals is feverishly working to deflect revenue risk tied to the impending patent expiration for its highly popular multiple sclerosis drug Copaxone. The company's attempts to block potential generic biosimilars from coming to market...
Mylan (MYL) Approaches New Upside Target of $50.18
Comtex SmarTrend(R) - Fri Mar 28, 9:08AM CDT
Shares of Mylan (NASDAQ:MYL) opened today above their pivot of $48.55 and have already reached the first level of resistance at $49.38. Analysts will be watching for a cross of the next upside pivot targets of $50.18 and $51.81.
Is Teva Pharmaceutical Industries Ltd Turning a Corner?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Mar 27, 5:30PM CDT
Once a darling of the health care space (and a frequent member of "buy and hold forever" lists), Teva Pharmaceuticals spent about three and a half years in the market's doghouse. Investors bailed out due to worries about competition in the...
Morning Movers in Biotech: Clovis Oncology, Inc., Exact Sciences Corporation, GlaxoSmithKline PLC, a
George Budwell, The Motley Fool - Motley Fool - Thu Mar 27, 8:00AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Mylan Wins Breach of Contract Case against GlaxoSmithKline
PR Newswire - Thu Mar 27, 6:00AM CDT
Mylan Inc. (Nasdaq: MYL) today announced that, after a trial in the United States District Court for the District of New Jersey, a jury returned a verdict in favor of Mylan in its breach of contract lawsuit against GlaxoSmithKline (GSK) relating to Paroxetine Hydrochloride Extended-release (ER) Tablets. The jury decided that GSK owes Mylan $106.7 million in damages.
First Week Of MYL May 17th Options Trading
at The Street - Wed Mar 26, 11:57AM CDT
Investors in Mylan Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MYL options chain for the new May 17th contracts and identified one put and...
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
SmarTrend Watching for Potential Rebound in Shares of Mylan After 4.16% Loss
Comtex SmarTrend(R) - Mon Mar 24, 4:06PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $49.26 to a high of $52.41. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $52.02 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
District Court Upholds Mylan's U.S. Patents on Perforomist® Inhalation Solution
PR Newswire - Mon Mar 24, 12:27PM CDT
Mylan Inc. (Nasdaq: MYL) today announced the United States District Court for the Northern District of West Virginia issued a decision upholding the validity of all patents asserted by Mylan, protecting Perforomist® (formoterol fumarate) Inhalation Solution. Mylan previously sued Teva alleging that Teva's Abbreviated New Drug Application (ANDA) for this product infringed four Mylan patents covering Perforomist. After a full trial, the Court entered a judgment finding infringement of the patents-in-suit, rejecting Teva's defenses, and enjoining Teva from making, using, offering to sell, selling or importing the inhalation product described in Teva's ANDA. The Court's decision also prevents Teva's ANDA, which has yet to receive a tentative approval from the U.S. Food and Drug Administration (FDA), from receiving final approval prior to expiration of U.S. Patent Nos. 6,667,344; 6,814,953; 7,348,362; and 7,462,645, which cover Perforomist through June 2021.
New Product Offerings, Development and Research Collaboration, Upcoming Investor Conference, and Board Election - Analyst Notes on CVS Caremark, Teva, Zoetis, McKesson, and Mylan
PR Newswire - Mon Mar 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding CVS Caremark Corporation (NYSE: CVS), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Zoetis, Inc. (NYSE: ZTS), McKesson Corporation (NYSE: MCK), and Mylan, Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
This Generic Drug Threat Won't Go Away
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sat Mar 22, 12:35PM CDT
Editor's Note: In the video, Michael Douglass refers to a quote from Mylan's president. The quote is actually from the president of Mylan's North American operations, Anthony Mauro. The Fool regrets the error. "The unintended consequences of...
Pharmaceutical Equities under Review -- Research on Zoetis, Mylan, AVANIR Pharma and Actavis
PR Newswire - Fri Mar 21, 10:11AM CDT
The trading session on Thursday, March 20, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ Composite closed at 4,319.29, up 0.27%. The S&P 500 finished the session 0.60% higher at 1,872.01. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Mylan Inc. (NASDAQ: MYL), AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR) and Actavis PLC (NYSE: ACT). Free technical research on ZTS, MYL, AVNR and ACT can be downloaded upon signing up at:
Mixed News for Pfizer: A Good Chance to Buy?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 19, 8:30AM CDT
Last week was unusually eventful for Pfizer . The company, along with partner Bristol-Myers Squibb won a supplementary approval for its Factor Xa inhibitor. Pfizer also released some better than expected data from a pneumonia vaccine study that...
After Yesterday's Rally of 1.69% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Mar 17, 4:05PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $52.86 to a high of $54.22. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $53.89 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Mylan Rises 1.69% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Mar 17, 4:04PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $52.86 to a high of $54.22. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $53.89 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
15.8% Return Seen to Date on SmarTrend Mylan Call (MYL)
Comtex SmarTrend(R) - Mon Mar 17, 11:17AM CDT
SmarTrend identified an Uptrend for Mylan (NASDAQ:MYL) on February 14th, 2014 at $46.13. In approximately 1 month, Mylan has returned 15.85% as of today's recent price of $53.44.
Mylan Earnings Hindsight: Down 6.5% in Last 18 Days (MYL)
Comtex SmarTrend(R) - Mon Mar 17, 6:58AM CDT
Two weeks ago on February 27th, 2014 Mylan (NASDAQ:MYL) reported earnings and analysts, on average, expected earnings of $0.75 on sales of $1.8 billion. The company actually reported EPS of $0.78 on sales of $1.8 billion, beating EPS estimates by $0.03 and beating revenue estimates by $3.1 million. Shares of Mylan have slipped from $56.27 to $52.63, representing a loss of 6.5%, since the company reported earnings 18 days ago.
4 Stocks Breaking Out on Big Volume
at The Street - Mon Mar 17, 6:57AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
